2014 Physician Quality Reporting System (PQRS)Measure-Applicability Validation (MAV) Process for Claims-Based Reporting of Individual Measures

01/28/2014

2014 PQRS Measure-Applicability Validation (MAV) Process for Claims-Based Reporting

The 2014 Physician Quality Reporting System (PQRS) incentive eligibility and payment adjustments will include validation processes. Under the claims-based reporting method of individual measure(s), the determination of satisfactory reporting will itself serve as a general validation because the analysis will assess whether quality-data codes (QDCs) are appropriately submitted in a sufficient proportion of the instances when a reporting opportunity exists. In addition, for those eligible professionals who satisfactorily submit QDCs for fewer than **nine** PQRS measures across **three domains or nine or more** PQRS measures across **less than three domains**, a measure-applicability validation (MAV) process will determine whether they should have submitted additional measures or additional measures with additional domains to be considered incentive eligible. Eligible Professionals with a specialty that has less than 9 measures or less than 3 domains would be subject to MAV but could still be eligible for incentive payment or avoid the payment adjustment. For payment adjustment considerations, those eligible professionals who satisfactorily submit QDCs for fewer than **three** PQRS measures, the MAV process will determine whether an eligible professional should have submitted for additional measures. Eligible professionals who fail MAV will not earn the PQRS incentive payment for 2014 and may be subject to the 2016 Payment Adjustment.

For further information, please refer to the PQRS Payment Adjustment documentation on the CMS website at http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/PQRS.

CMS will apply a two-step validation process to operationalize MAV: (1) a "clinical/domain relation" test, and (2) a "minimum threshold" test. CMS may determine that it is necessary to modify the measure-applicability validation process after the start of the 2014 reporting period. However, any changes will result in the process being applied more leniently, thereby (1) allowing a greater number of eligible professionals to pass validation and (2) causing no eligible professional who would otherwise have passed to fail.

Prerequisites for MAV

- Eligible professionals who satisfactorily report QDCs for **only one to eight** PQRS measures across **one or more domains**, **OR** eligible professionals who satisfactorily report QDCs for **nine or more** PQRS measures across **less than three domains**
- Eligible professionals must satisfactorily report for at least 50 percent of their eligible patients or encounters for each measure
    - To receive 2014 incentive payment, CMS will analyze claims data to validate if more measures/domains may have been applicable for reporting
    - To avoid 2016 payment adjustment, if only one or two measures are satisfactorily report , CMS will analyze claims data to validate if more measures may have been applicable for reporting
        - EPs that satisfactorily report three or more measures across one or more domains will not be subject to MAV for payment adjustment purposes, but ***will*** be subject to MAV to determine if more measures/domains could have been submitted for 2014 incentive eligibility.
- A performance rate greater than 0% [or less than 100% where a lower performance rate indicates better performance (inverse measures)]
- Eligible professionals who do not submit **any** QDCs for **any other** measure will be subject to the MAV process

Please refer to the *2014 Physician Quality Reporting System (PQRS) Measure-Applicability Validation (MAV) Process Flow for Claims-Based Reporting of Individual Measures for Incentive Eligibility* for further guidance. Selection of eligible professionals for MAV may be accomplished through a sampling mechanism

Step 1: Clinical Relation/Domain Test

The clinical relation/domain test is the first step in the two-step MAV that will be applied to those who are subject to the validation process of reported measures **OR** domains. This test is based on: (1) an extension of the statutory presumption that if an eligible professional submits data for a measure, then that measure applies to her/his practice and (2) the concept that if one measure in a cluster of measures related to a particular clinical topic or eligible professional service is applicable to an eligible professional's practice, then other closely-related measures (measures in that same cluster) **may** also be applicable.

For those eligible professionals who satisfactorily submit QDCs for nine PQRS measures for **only one or two domains**, there will be a determination if additional measures with additional domains may also be applicable to the eligible professional based on the clinical cluster to earn the 2014 PQRS incentive.

The following is an example of how the clinical relation/domain test will be applied: An eligible professional who is subject to MAV submitted QDCs for one of the PQRS measures related to diabetes. The eligible professional's claims will then be analyzed using the minimum threshold test described below in Step 2 (Minimum Threshold Test) to determine whether any of the other diabetes measure(s) in the diabetes cluster could also have been submitted.

Please note that there are several measures that are contained within multiple clusters. For example, Measure 130: Documentation of Current Medications in the Medical Record is found within 10 different claims-based MAV clusters. The list of clusters of related measures and the PQRS measures that are included within each cluster are presented below. CMS may determine this list should be modified to apply the MAV process more leniently. Any made modifications will be published on the CMS PQRS website as soon as possible after determination.

Clusters of Clinically Related Measures Used in Step 1 of the 2014 PQRS MAV for Claims-Based Reporting of Individual Measures

Cluster Number 1: General Preventive Care

Measure Number	Domain	Measure Title
110	Community/ Population Health	Preventive Care and Screening: Influenza Immunization
111	Effective Clinical Care	Pneumonia Vaccination Status for Older Adults
112	Effective Clinical Care	Breast Cancer Screening
113	Effective Clinical Care	Colorectal Cancer Screening
128	Community/ Population Health	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up
130	Patient Safety	Documentation of Current Medications in the Medical Record
226	Community/ Population Health	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
317	Community/ Population Health	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented

Cluster Number 2: Urinary Incontinence Care

Measure Number	Domain	Measure Title
48	Effective Clinical Care	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
49	Effective Clinical Care	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older
50	Person and Caregiver-Centered Experience and Outcomes	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older

Cluster Number 3: Diabetic Care

Measure Number	Domain	Measure Title
1	Effective Clinical Care	Diabetes: Hemoglobin A1c Poor Control
2	Effective Clinical Care	Diabetes: Low Density Lipoprotein (LDL-C) Control (<100 mg/dL)
117	Effective Clinical Care	Diabetes: Eye Exam
119	Effective Clinical Care	Diabetes: Medical Attention for Nephropathy
128	Community/ Population Health	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up
130	Patient Safety	Documentation of Current Medications in the Medical Record
163	Effective Clinical Care	Diabetes: Foot Exam
226	Community/ Population Health	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

Cluster Number 4: Lung Care

Measure Number	Domain	Measure Title
51	Effective Clinical Care	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation
52	Effective Clinical Care	Chronic Obstructive Pulmonary Disease (COPD): Inhaled Bronchodilator Therapy
130	Patient Safety	Documentation of Current Medications in the Medical Record
231	Effective Clinical Care	Asthma: Tobacco Use: Screening - Ambulatory Care Setting
232	Effective Clinical Care	Asthma: Tobacco Use: Intervention - Ambulatory Care Setting

Cluster Number 5: Emergency Care

Measure Number	Domain	Measure Title
28	Effective Clinical Care	Aspirin at Arrival for Acute Myocardial Infarction (AMI)
54	Effective Clinical Care	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain
55	Effective Clinical Care	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope
56	Effective Clinical Care	Emergency Medicine: Community-Acquired Bacterial Pneumonia (CAP): Vital Signs
59	Effective Clinical Care	Emergency Medicine: Community-Acquired Bacterial Pneumonia (CAP): Empiric Antibiotic
254	Effective Clinical Care	Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain
255	Effective Clinical Care	Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure

Cluster Number 6: Cancer Care

Measure Number	Domain	Measure Title
110	Community/ Population Health	Preventive Care and Screening: Influenza Immunization
67	Effective Clinical Care	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow
68	Effective Clinical Care	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy
69	Effective Clinical Care	Hematology: Multiple Myeloma: Treatment with Bisphosphonates
70	Effective Clinical Care	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry
71	Effective Clinical Care	Breast Cancer: Hormonal Therapy for Stage IC - IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer
72	Effective Clinical Care	Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients
102	Efficiency and Cost Reduction	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
104	Effective Clinical Care	Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients
156	Patient Safety	Oncology: Radiation Dose Limits to Normal Tissues
194	Effective Clinical Care	Oncology: Cancer Stage Documented
262	Patient Safety	Image Confirmation of Successful Excision of Image-Localized Breast Lesion
263	Effective Clinical Care	Preoperative Diagnosis of Breast Cancer

Cluster Number 7: Osteoporosis Care

Measure Number	Domain	Measure Title
24	Communication and Care Coordination	Osteoporosis: Communication with the Physician Managing On-Going Care Post-Fracture of Hip, Spine, or Distal Radius for Men and Women Aged 50 Years and Older
39	Effective Clinical Care	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
40	Effective Clinical Care	Osteoporosis: Management Following Fracture of Hip, Spine, or Distal Radius for Men and Women Aged 50 Years and Older
41	Effective Clinical Care	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older

Cluster Number 8: Ear, Nose, & Throat Care

Measure Number	Domain	Measure Title
91	Effective Clinical Care	Acute Otitis Externa (AOE): Topical Therapy
93	Communication and Care Coordination	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use

Cluster Number 9: Pathology

Measure Number	Domain	Measure Title
99	Effective Clinical Care	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade
100	Effective Clinical Care	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade
249	Effective Clinical Care	Barrett's Esophagus
250	Effective Clinical Care	Radical Prostatectomy Pathology Reporting
251	Effective Clinical Care	Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients

Cluster Number 10: Diagnostic Imaging

Measure Number	Domain	Measure Title
145	Patient Safety	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy
146	Efficiency and Cost Reduction	Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening
147	Communication and Care Coordination	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy
195	Effective Clinical Care	Radiology: Stenosis Measurement in Carotid Imaging Reports
225	Communication and Care Coordination	Radiology: Reminder System for Mammograms

Cluster Number 11: Depression

Measure Number	Domain	Measure Title
106	Effective Clinical Care	Adult Major Depressive Disorder (MDD): Comprehensive Depression Evaluation: Diagnosis and Severity
107	Effective Clinical Care	Adult Major Depressive Disorder (MDD): Suicide Risk Assessment
134	Community/ Population Health	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan
226	Community/ Population Health	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

Cluster Number 12: Eye Care

Measure Number	Domain	Measure Title
12	Effective Clinical Care	Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation
14	Effective Clinical Care	Age-Related Macular Degeneration (AMD): Dilated Macular Examination
18	Effective Clinical Care	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
19	Effective Clinical Care	Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
140	Effective Clinical Care	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement
141	Communication and Care Coordination	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care

Cluster Number 13: Renal Disease Care

Measure Number	Domain	Measure Title
121	Effective Clinical Care	Adult Kidney Disease: Laboratory Testing (Lipid Profile)
122	Effective Clinical Care	Adult Kidney Disease: Blood Pressure Management
123	Effective Clinical Care	Adult Kidney Disease: Patients on Erythropoiesis-Stimulating Agent (ESA) Hemoglobin Level > 12.0 g/dL
327	Effective Clinical Care	Pediatric Kidney Disease: Adequacy of Volume Management
328	Effective Clinical Care	Pediatric Kidney Disease: ESRD Patients Receiving Dialysis: Hemoglobin Level < 10g/dL

Cluster Number 14: Stroke Care

Measure Number	Domain	Measure Title
31	Effective Clinical Care	Stroke and Stroke Rehabilitation: Venous Thromboembolism (VTE)Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage
32	Effective Clinical Care	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy
35	Effective Clinical Care	Stroke and Stroke Rehabilitation: Screening for Dysphagia
36	Effective Clinical Care	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered

Cluster Number 15: Surgical Care

Measure Number	Domain	Measure Title
20	Patient Safety	Perioperative Care: Timing of Prophylactic Parenteral Antibiotic – Ordering Physician
21	Patient Safety	Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin
22	Patient Safety	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Non-Cardiac Procedures)
23	Patient Safety	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)
43	Effective Clinical Care	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery
44	Effective Clinical Care	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery
45	Patient Safety	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Cardiac Procedures)
157	Patient Safety	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection
172	Effective Clinical Care	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula

Cluster Number 16: Joint Care

Measure Number	Domain	Measure Title
108	Effective Clinical Care	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
109	Person and Caregiver-Centered Experience and Outcomes	Osteoarthritis (OA): Function and Pain Assessment
131	Community/ Population Health	Pain Assessment and Follow-Up
142	Effective Clinical Care	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications

Cluster Number 17: Anesthesia Care

Measure Number	Domain	Measure Title
30	Patient Safety	Perioperative Care: Timing of Prophylacitc Antibiotic—Administering Physician
76	Patient Safety	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol *When reporting #76 alone, it is not subject to MAV*

Cluster Number 18: Anesthesia Care 2

Measure Number	Domain	Measure Title
76	Patient Safety	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol
193	Patient Safety	Perioperative Temperature Management *When reporting #76 alone, it is not subject to MAV*

Cluster Number 19: Ischemic Vascular Disease Care

Measure Number	Domain	Measure Title
128	Community/ Population Health	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up
130	Patient Safety	Documentation of Current Medications in the Medical Record
204	Effective Clinical Care	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
226	Community/ Population Health	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
241	Effective Clinical Care	Ischemic Vascular Disease (IVD): Complete Lipid Profile and LDL-C Control (<100 mg/dL)

Cluster Number 20: Chronic Wound Care

Measure Number	Domain	Measure Title
130	Patient Safety	Documentation of Current Medications in the Medical Record
226	Community/ Population Health	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
245	Effective Clinical Care	Chronic Wound Care: Use of Wound Surface Culture Technique in Patients with Chronic Skin Ulcers (Overuse Measure)
246	Effective Clinical Care	Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers (Overuse Measure)

Cluster Number 21: Epilepsy Care

Measure Number	Domain	Measure Title
130	Patient Safety	Documentation of Current Medications in the Medical Record
266	Effective Clinical Care	Epilepsy: Seizure Types(s) and Current Seizure Frequency(ies)
267	Effective Clinical Care	Epilepsy: Documentation of Etiology of Epilespy or Epilespy Syndrome
268	Effective Clinical Care	Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy

Cluster Number 22: Substance Use Disorders Care

Measure Number	Domain	Measure Title
130	Patient Safety	Documentation of Current Medications in the Medical Record
226	Community/ Population Health	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
247	Effective Clinical Care	Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence
248	Effective Clinical Care	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence

Cluster Number 23: Endoscopy and Polyp Surveillance

Measure Number	Domain	Measure Title
185	Communication and Care Coordination	Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use
320	Communication and Care Coordination	Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients

Cluster Number 24: Chiropractic Care & Physical/Occupational Therapy

Measure Number	Domain	Measure Title
131	Community/ Population Health	Pain Assessment and Follow-Up
182	Communication and Care Coordination	Functional Outcome Assessment

Cluster Number 25: General Practice Care

Measure Number	Domain	Measure Title
128	Community/ Population Health	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up
130	Patient Safety	Documentation of Current Medications in the Medical Record
154	Patient Safety	Falls: Risk Assessment
155	Communication and Care Coordination	Falls: Plan of Care
181	Patient Safety	Elder Maltreatment Screen and Follow-Up Plan
6	Effective Clinical Care	Coronary Artery Disease (CAD): Antiplatelet Therapy

Cluster Number 26: Cardiac Care

Measure Number	Domain	Measure Title
6	Effective Clinical Care	Coronary Artery Disease (CAD): Antiplatelet Therapy
130	Patient Safety	Documentation of Current Medications in the Medical Record
236	Effective Clinical Care	Controlling High Blood Pressure
326	Patient Safety	Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy

Cluster Number 27: Audiology Care

Measure Number	Domain	Measure Title
130	Patient Safety	Documentation of Current Medications in the Medical Record
261	Communication and Care Coordination	Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness

Measures Not Included Within a Cluster in 2014 PQRS
For 2014 MAV, CMS will not include measures that are deemed to be generally or broadly applicable to all or many Medicare patients and, therefore, potentially unreasonable to attribute to individual eligible professionals using claims-based data. Other measures are not included in a cluster of closely clinically related measures for other clinical or technical reasons, such as the measure may not fit in any cluster.

Measures not included within a cluster for 2014 claims-based MAV may or may not be included in groupings of measures used in validation protocols for other mechanisms of data submission, or for other purposes, or programs. These measures may also, in subsequent program years, be included in a MAV cluster for claims-based or registry-based participation in PQRS.

Measure 46 - Medication Reconciliation
Measure 47 - Advance Care Plan

Prior to performing the analysis to determine satisfactory reporting, CMS may determine that additional PQRS measures should not be included within a cluster for claims-based MAV. Any additions to this list will be published on the CMS PQRS website as soon as possible after determination.

Step 2: Minimum Threshold Test
This second step will be applied to those who are subject to MAV and who have potential additional measures that could have been submitted identified during the clinical relation/domain test.

The minimum threshold test is based on the concept that during the 2014 reporting period (January 1, 2014 through December 31, 2014), if an eligible professional treated more than a certain number of Medicare patients with a condition to which a certain measure applied (that is, the eligible professional treated more than a "threshold" number of patients or encounters), then that eligible professional should be accountable for submitting the QDC(s) for that measure. The common minimum threshold, based on statistical and clinical frequency considerations, will not be less than 15 patients (or encounters) for the 12-month reporting period for each 2014 PQRS measure.

The following are examples of how the minimum threshold test will be applied: An endocrinologist treated 20 Medicare patients with diabetes during the 12-month reporting period for 2014. If that endocrinologist is subject to validation and was found to have submitted a QDC for at least one of the diabetes measures under the clinical relation test, then the physician would be deemed responsible for submitting QDCs for the other PQRS diabetes cluster measures and will not earn the 2014 incentive payment. Alternatively, if an internist was subject to validation and was found to have submitted a QDC for at least one of the diabetes measures under the clinical relation test, but treated only two Medicare patients with diabetes during the same period, then the internist would not be responsible for submitting the additional diabetes measures and would not be precluded from receiving an incentive payment.

During the reporting period, CMS will determine a minimum threshold for each individual PQRS measure based on analysis of Part B claims data. However, no threshold will fall below the common threshold of 15 patients (or encounters) described above.

Other Program Integrity Considerations
QDCs submitted on claims must be supported in medical record documentation. Other laws and regulations relating to Medicare program integrity may also apply to PQRS.

Measures Reported via Registry, Measures Group, Electronic Health Record (EHR) or Web-Interface Only – Not Applicable to Claims-Based MAV

The following list of PQRS measures are available through registries, measure groups, EHR, or Web-Interface mechanisms only, therefore, are not subject to the claims-based MAV. Measures that are available via registry reporting would be applicable within registry MAV.

Measure 5	Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
Measure 7	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)
Measure 8	Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
Measure 9	Anti-depressant Medication Management
Measure 33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge
Measure 53	Asthma: Pharmacologic Therapy for Persistent Asthma – Ambulatory Care Setting
Measure 64	Asthma: Assessment of Asthma Control – Ambulatory Care Setting
Measure 65	Appropriate Treatment for Children with Upper Respiratory Infection (URI)
Measure 66	Appropriate Testing for Children with Pharyngitis
Measure 81	Adult Kidney Disease: Hemodialysis Adequacy: Solute
Measure 82	Adult Kidney Disease: Peritoneal Dialysis Adequacy: Solute
Measure 83	Hepatitis C: Confirmation of Hepatitis C Viremia
Measure 84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment
Measure 85	Hepatitis C: HCV Genotype Testing Prior to Treatment
Measure 87	Hepatitis C: Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Testing Between 4-12 Weeks After Initiation of Treatment
Measure 116	Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis
Measure 118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)
Measure 126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation
Measure 127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear
Measure 137	Melanoma: Continuity of Care-Recall System
Measure 138	Melanoma: Coordination of Care
Measure 143	Oncology: Medical and Radiation – Pain Intensity Quantified
Measure 144	Oncology: Medical and Radiation – Plan of Care for Pain
Measure 148	Back Pain: Initial Visit
Measure 149	Back Pain: Physical Exam
Measure 150	Back Pain: Advice for Normal Activities
Measure 151	Back Pain: Advice Against Bed Rest
Measure 159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage Performed
Measure 160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis
Measure 164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation
Measure 165	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate
Measure 166	Coronary Artery Bypass Graft (CABG): Stroke
Measure 167	Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure
Measure 168	Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration
Measure 169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge
Measure 170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge
Measure 171	Coronary Artery Bypass Graft (CABG): Anti-Lipid Treatment at Discharge
Measure 173	Preventive Care and Screening: Unhealthy Alcohol Use -- Screening
Measure 176	Rheumatoid Arthritis (RA): Tuberculosis Screening
Measure 177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity
Measure 178	Rheumatoid Arthritis (RA): Functional Status Assessment

Measure 179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis
Measure 180	Rheumatoid Arthritis (RA): Glucocorticoid Management
Measure 183	Hepatitis C: Hepatitis A Vaccination in Patients with Hepatitis C Virus (HCV)
Measure 187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy
Measure 191	Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
Measure 192	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures
Measure 197	Coronary Artery Disease (CAD): Lipid Control
Measure 198	Heart Failure: Left Ventricular Ejection Fraction (LVEF) Assessment
Measure 205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia,Gonorrhea, and Syphilis
Measure 217	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments
Measure 218	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Hip Impairments
Measure 219	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lower Leg, Foot or Ankle Impairments
Measure 220	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments
Measure 221	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments
Measure 222	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist or Hand Impairments
Measure 223	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs, or Other General Orthopedic Impairments
Measure 224	Melanoma: Overutilization of Imaging Studies in Melanoma
Measure 228	Heart Failure (HF): Left Ventricular Function (LVF) Testing
Measure 233	Thoracic Surgery: Recording of Performance Status Prior to Lung or Esophageal Cancer Resection
Measure 234	Thoracic Surgery: Pulmonary Function Tests Before Major Anatomic Lung Resection (Pneumonectomy, Lobectomy, or Formal Segmentectomy)
Measure 238	Use of High-Risk Medications in the Elderly
Measure 239	Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents
Measure 240	Childhood Immunization Status
Measure 242	Coronary Artery Disease (CAD): Symptom Management
Measure 243	Cardiac Rehabilitation Patient Referral from an Outpatient Setting
Measure 257	Statin Therapy at Discharge after Lower Extremity Bypass (LEB)
Measure 258	Rate of Open Repair of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7)
Measure 259	Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home Post-Operative Day #2)
Measure 260	Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home Post-Operative #2)
Measure 264	Sentinel Lymph Node Biopsy for Invasive Breast Cancer
Measure 265	Biopsy Follow-Up
Measure 269	Inflammatory Bowel Disease (IBD): Type, Anatomic Location and Activity All Documented
Measure 270	Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy
Measure 271	Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Related Iatrogenic Injury – Bone Loss Assessment
Measure 272	Inflammatory Bowel Disease (IBD): Preventive Care: Influenza Immunization
Measure 273	Inflammatory Bowel Disease (IBD): Preventive Care: Pneumococcal Immunization
Measure 274	Inflammatory Bowel Disease (IBD): Testing for Latent Tuberculosis (TB) Before Initating Anti-TNF (Tumor Necrosis Factor) Therapy

Measure 275	Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy
Measure 276	Sleep Apnea: Assessment of Sleep Symptoms
Measure 277	Sleep Apnea: Severity Assessment at Initial Diagnosis
Measure 278	Sleep Apnea: Positive Airway Pressure Therapy Prescribed
Measure 279	Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy
Measure 280	Dementia: Staging of Dementia
Measure 281	Dementia: Cognitive Assessment
Measure 282	Dementia: Functional Status Assessment
Measure 283	Dementia: Neuropsychiatric Symptom Assessment
Measure 284	Dementia: Management of Neuropsychiatric Symptoms
Measure 285	Dementia: Screening for Depressive Symptoms
Measure 286	Dementia: Counseling Regarding Safety Concerns
Measure 287	Dementia: Counseling Regarding Risks of Driving
Measure 288	Dementia: Caregiver Education and Support
Measure 289	Parkinson's Disease: Annual Parkinson's Disease Diagnosis Review
Measure 290	Parkinson's Disease: Psychiatric Disorders or Disturbances Assessment
Measure 291	Parkinson's Disease: Cognitive Impairment or Dysfunction Assessment
Measure 292	Parkinson's Disease: Querying about Sleep Disturbances
Measure 293	Parkinson's Disease: Rehabilitative Therapy Options
Measure 294	Parkinson's Disease: Parkinson's Disease Medical and Surgical Treatment Options Reviewed
Measure 295	Hypertension: Appropriate Use of Aspirin or Other Antithrombotic Therapy
Measure 296	Hypertension: Complete Lipid Profile
Measure 297	Hypertension: Urine Protein Test
Measure 298	Hypertension: Annual Serum Creatinine Test
Measure 299	Hypertension: Diabetes Mellitus Screening Test
Measure 300	Hypertension: Blood Pressure Control
Measure 301	Hypertension: Low Density Lipoprotein (LDL-C) Control
Measure 302	Hypertension: Dietary and Physical Activity Modifications Appropriately Prescribed
Measure 303	Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery
Measure 304	Cataracts: Patient Satisfaction within 90 Days following Cataract Surgery
Measure 305	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment
Measure 309	Cervical Cancer Screening
Measure 310	Chlamydia Screening for Women
Measure 311	Use of Appropriate Medications for Asthma
Measure 312	Use of Imaging Studies for Low Back Pain
Measure 316	Preventive Care and Screening: Cholesterol – Fasting Low Density Lipoprotein (LDL-C) Test Performed: AND Risk-Stratified Fasting LDL-C
Measure 318	Falls: Screening for Future Fall Risk
Measure 319	Diabetes Composite: Optimal Diabetes Care
Measure 321	CG-CAHPS Clinician/Group Survey
Measure 322	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients
Measure 323	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI)
Measure 324	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low Risk Patients
Measure 325	Adult Major Depressive Disorder (MDD): Coordination of Care of Patients with Specific Comorbid Conditions
Measure 329	Adult Kidney Disease: Catheter Use at Initiation of Hemodialysis

Measure 330	Adult Kidney Disease: Catheter Use for Greater Than or Equal to 90 Days
Measure 331	Adult Sinusitis: Antibiotic Prescribed for Acute Sinusitis (Appropriate Use)
Measure 332	Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin Prescribed for Patients with Acute Bacterial Sinusitis
Measure 333	Adult Sinusitis: Computerized Tomography (CT) for Acute Sinusitis (Overuse)
Measure 334	Adult Sinusitis: More than One Computerized Tomography (CT) Scan Within 90 Days for Chronic Sinusitis (Overuse)
Measure 335	Maternity Care: Elective Delivery or Early Induction Without Medical Indication at ≥ 37 and < 39 Weeks
Measure 336	Maternity Care: Post-Partum Follow-Up and Care Coordination
Measure 337	Tuberculosis Prevention for Psoriasis and Psoriatic Arthritis Patients on a Biological Immune Response Modifier
Measure 338	HIV Viral Load Suppression
Measure 339	Prescription of HIV Antiretroviral Therapy
Measure 340	HIV Medical Visit Frequency
Measure 341	Gap in HIV Medical Visits
Measure 342	Pain Brought Under Control Within 48 Hours
Measure 343	Screening Colonoscopy Adenoma Detection Rate
Mesaure 344	Rate of Carotid Artery Stenting (CAS) for Asymptomatic Patients, Without Major Complications (Discharged to Home by Post-Operative Day #2)
Measure 345	Rate of Postoperative Stroke or Death in Asymptomatic Patients Undergoing Carotid Artery Stenting (CAS)
Measure 346	Rate of Postoperative Stroke or Death in Asymptomatic Patients Undergoing Carotid Endarterectomy (CEA)
Measure 347	Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) Who Die While in Hospital
Measure 348	HRS-3: Implantable Cardioverter-Defibrillator (ICD) Complications Rate
Measure 349	Optimal Vascular Care Composite
Measure 350	Total Knee Replacement: Shared Decision-Making: Trial of Conservative (Non-surgical) Therapy
Measure 351	Total Knee Replacement: Venous Thromboembolic and Cardiovascular Risk Evaluation
Measure 352	Total Knee Replacement: Preoperative Antibiotic Infusion with Proximal Tourniquet
Measure 353	Total Knee Replacement: Identification of Implanted Prosthesis in Operative Report
Measure 354	Anastomotic Leak Intervention
Measure 355	Unplanned Reoperation within the 30 Day Postoperative Period
Measure 356	Unplanned Hospital Readmission within 30 Days of Principal Procedure
Measure 357	Surgical Site Infection (SSI)
Measure 358	Patient-Centered Surgical Risk Assessment and Communication
Measure 359	Optimizing Patient Exposure to Ionizing Radiation: Utilization of a Standardized Nomenclature for Computed Tomography (CT) Imaging Description
Measure 360	Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies
Measure 361	Optimizing Patient Exposure to Ionizing Radiation: Reporting to a Radiation Dose Index Registry
Measure 362	Optimizing Patient Exposure to Ionizing Radiation: Computed Tomography (CT) Images Available for Patient Follow-up and Comparison Purposes
Measure 363	Optimizing Patient Exposure to Ionizing Radiation: Search for Prior Computed Tomography (CT) Imaging Studies Through a Secure, Authorized, Media-Free, Shared Archive
Measure 364	Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines
Measure 365	Hemoglobin A1c Test for Pediatric Patients

Measure 366	ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication
Measure 367	Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use
Measure 368	HIV/AIDS: Medical Visit
Measure 369	Pregnant women that had HBsAg testing
Measure 370	Depression Remission at Twelve Months
Measure 371	Depression Utilization of the PHQ-9 Tool
Measure 372	Maternal Depression Screening
Measure 373	Hypertension: Improvement in Blood Pressure
Measure 374	Closing the referral loop: receipt of specialist report
Measure 375	Functional Status Assessment for Knee Replacement
Measure 376	Functional Status Assessment for Hip Replacement
Measure 377	Functional Status Assessment for Complex Chronic Conditions
Measure 378	Children Who Have Dental Decay or Cavities
Measure 379	Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists
Measure 380	ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range
Measure 381	HIV/AIDS: RNA Control for Patients with HIV
Measure 382	Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment